Equitable Access Review of CEPI’s Chikungunya Partnership Agreements

This Equitable Access Review (hereafter the Review) of CEPI’s Chikungunya vaccine development agreements was commissioned by CEPI in 2024 as an external review of how equitable access has been incorporated into CEPI’s partnerships and planning leading to the licensure of the first Chikungunya vaccine by the US FDA in 2023 and other candidates now in late stage development. This Review aims to evaluate and generate lessons learned on how CEPI performed against its commitment to equitable access, and how these learnings may contribute to further enhance CEPI’s agreements and activities moving forward. The Center for Transformational Health Law (CTHL) at the O’Neill Institute for National and Global Law at Georgetown University, was selected to undertake the Review.